Obsidian Therapeutics is pioneering controllable cell and gene therapies to deliver transformative outcomes for patients with intractable diseases. In this interview, CEO Paul Wotton discusses the applications of Obsidian’s cytoDrive technology in cell and gene therapy products to control expression of proteins for enhanced therapeutic efficacy. Please describe the story behind the company: What sparked the idea, and […]

After a decade of breakthroughs in biopharma, highlighted by the development of a vaccine against the novel coronavirus in just nine months, expectations of 2022 couldn’t be higher. From a continued focus on oncology and the resurgence of risk appetite in neuroscience, many expect a rebound for the life sciences capital markets paired with a year […]

Cartesian Therapeutics is developing non-permanent cell therapies that can be used soon after diagnosis and address a wide range of diseases beyond cancer. The biotech’s approach to cell engineering relies upon RNA rather than DNA to effect changes within the cells. The benefit, Cartesian President and CEO Murat Kalayoglu, M.D., Ph.D. told BioSpace, is that “our […]